Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.45 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL137308 | 0.80 | LMNA (0.65) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL10244942 | 0.80 | SMN1; SMN2 (0.56) | LMNASMN1; SMN2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL2083526 | 0.77 | CTSK (0.53) | LMNASMN1; SMN2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL31613224 | 0.75 | HTT (0.52) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL3107991 | 0.75 | LMNA (0.58) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL20213724 | 0.74 | LMNA (0.49) | LMNASMN1; SMN2CHRNB2CHRNB4CHRNA3 | |
| Aniline SCHEMBL27715502 | 0.74 | LMNA (0.56) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL9573674 | 0.72 | LMNA (0.55) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL17264303 | 0.72 | LMNA (0.47) | LMNASLC1A3SLC1A1ALDH1A1 | |
| SCHEMBL29118548 | 0.72 | TSHR (0.41) | LMNAHTTL3MBTL1MAPTSLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160324974-A1 | METHOD FOR PREPARING A POLYMERIC REAGENT | NEKTAR THERAPEUTICS | 2016-11-10 | — | — | US | disclosed |
| US-9399070-B2 | Compositions comprising a polymeric reagent and a pharmacologically active agent | NEKTAR THERAPEUTICS (US) | 2016-07-26 | — | — | US | disclosed |
| US-20150328331-A1 | Compositions Comprising a Polymeric Reagent and a Pharmacologically Active Agent | NEKTAR THERAPEUTICS (US) | 2015-11-19 | — | — | US | disclosed |
| US-9044516-B2 | Pharmaceutical compositions of conjugates formed from polymer derivatives having particular atom arrangements | NEKTAR THERAPEUTICS (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140227218-A1 | Pharmaceutical Compositions of Conjugates Formed From Polymer Derivatives Having Particular Atom Arrangements | NEKTAR THERAPEUTICS (US) | 2014-08-14 | — | — | US | disclosed |
| US-8633277-B2 | Methods for forming polymer-drug conjugates | NEKTAR THERAPEUTICS (US) | 2014-01-21 | — | — | US | disclosed |
| US-20110178242-A1 | Methods for Forming Polymer-Drug Conjugates | NEKTAR THERAPEUTICS (US) | 2011-07-21 | — | — | US | disclosed |
| US-7947261-B2 | Moiety is positioned between a water-soluble polymer and a reactive group; water soluble polymer such as polyethylene glycol containing a urethane linkage moiety for example, and a reactive group for conjugating with biodrugs | NEKTAR THERAPEUTICS (US) | 2011-05-24 | — | — | US | disclosed |
| US-7887789-B2 | Polymer derivatives having particular atom arrangements | NEKTAR THERAPEUTICS (US) | 2011-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140227218-A1 | Pharmaceutical Compositions of Conjugates Formed From Polymer Derivatives Having Particular Atom Arrangements | PAICS, UGT2B7, LPXN | LMNA 3131/4885SMN1; SMN2 2314/4885CHRNB2 1613/4885 |
| US-20150328331-A1 | Compositions Comprising a Polymeric Reagent and a Pharmacologically Active Agent | PHOSPHO1, PAICS, FCGRT | LMNA 1599/4885SMN1; SMN2 2313/4885CHRNB2 1979/4885 |
| US-20160324974-A1 | METHOD FOR PREPARING A POLYMERIC REAGENT | SI, PAICS, DNPEP | LMNA 1848/4885SMN1; SMN2 2744/4885CHRNB2 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.